A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Summary

This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes mellitus (T2DM).

Timeline

Start

2023-03-31

Primary completion

2023-06-16

Completion

2023-06-20

Outcome

Missed primary endpoint

registry analysis (superiority test); C21 Treatment vs Placebo Treatment; p = 0.1925; Mean Difference (Final Values) -0.124 (90% CI -0.285 to 0.037); ANOVA NCT05831644 ↗

Drugs

Indications